ENXTPA:IPNPharmaceuticals
Has Ipsen’s Multi Year Surge Left Much Upside After Recent Pipeline Progress?
Wondering if Ipsen is still a smart buy after its strong multi year run, or if most of the upside is already priced in? This breakdown will help you decide whether the current tag looks compelling or stretched.
The stock has been roughly flat over the last week and month, but it is still up 9.2% year to date, 13.5% over the past year, and a hefty 90.2% over five years, which naturally raises questions about future return potential and changing risk perceptions.
Recent headlines have focused...